The costs and expenses are worth it if they allow the company to be properly valued. Clearly Australians don't know how to value biotech. OCC has FDA and EU approvals, a global distribution cash deal with the world leader in dental products, but it is valued less than before it achieved these milestones. It's absurd.
OCC Trading, page-1311
-
- There are more pages in this discussion • 425 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.005(1.35%) |
Mkt cap ! $76.49M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.5¢ | 36.5¢ | $52.06K | 142.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20235 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 4244 | 1 |
View Market Depth
| Last trade - 14.42pm 20/08/2024 (20 minute delay) ? |
| OCC (ASX) Chart |